Journal of Clinical Oncology
Articles in this Issue
Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-03 study of participants (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) vs chemotherapy (chemo).
1001 Background: In ASCENT-03, first-line (1L) SG led to a clinically meaningful improvement in PFS vs chemo (median, 9.7...
Obesity paradox in gastrointestinal cancer patients on immunotherapy: A retrospective multi-institutional US cohort study.
11016 Background: Obesity is a well-established risk factor for different types of cancers, including gastric cancers. How...
Pilot study of allostatic load, area deprivation, and race in endometrioid endometrial cancer.
e17631 Background: Area Deprivation Index (ADI) is a validated neighborhood-level metric of socioeconomic disadvantage. Hi...
Knowledge and uptake of HPV vaccination among Hispanic women and vaccine-eligible children.
e17531 Background: Despite the advent of effective and affordable prevention methods, disparities in HPV-related cancers p...
Drivers of non-evaluable imaging timepoints in oncology clinical trials.
e23021 Background: Robust imaging data are critical to endpoint determination in oncology clinical trials and regulatory d...
Effectiveness of CAR-T cells engineered with TGF-βr/IL-9R domain-swapped chimeric receptor and membrane-bound IL-2 for treatment of CEA+ solid tumors.
e14502 Background: Despite recent progress, CAR-T therapy for solid tumors remains limited by poor infiltration, an immuno...
Enhancing oncology board exam readiness through a longitudinal review curriculum.
9031 Background: Due to the rapid pace of medical advancements in cancer care in recent years, passing the medical oncolog...
Real-world clinical outcomes of neoadjuvant pembrolizumab among patients with early-stage triple-negative breast cancer (esTNBC) in a US community oncology setting.
e12630 Background: In the KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy (P+C) improved pathological compl...
ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC).
1013 Background: In the phase 3 ASCENT-04/KEYNOTE-D19 study (NCT05382286) SG + pembro showed significant and clinically me...
Breast cancer screening and detection after the 2024 USPSTF recommendation for women aged 40–49.
11126 Background: In April 2024, the US Preventive Services Task Force (USPSTF) expanded its biennial screening mammograph...
Clinical outcomes of venetoclax with and without azole antifungals in acute myeloid leukemia: A large real-world cohort study.
e18540 Background: Venetoclax is widely used in the treatment of acute myeloid leukemia (AML) and is frequently co-adminis...
Turning silence into rhythm: Outcomes of a school-based <i>Cancer Olympiad</i> in India.
9016 Background: Late-stage presentation continues to account for nearly 70% of cancer diagnoses in low- and middle-income...
Evaluating the prognostic performance of an AI-based model in clinically low-risk HR+/HER2− early breast cancer.
552 Background: Accurate prediction of recurrence risk in early HR+/HER2- breast cancer remains central to adjuvant treatm...
Mitochondrial size as a potential factor in colorectal cancer metastasis.
e15546 Background: The accelerated progression of colorectal cancer, with frequent recurrences and distant metastases, hig...
Development and internal validation of a clinical prognostic model for SMARCB1-deficient renal medullary carcinoma (RMC).
e16535 Background: RMC is a rare and highly aggressive malignancy that predominantly affects young individuals with sickle...
Real-world outcomes and prognostic risk stratification of neoadjuvant immunotherapy for stage III lung squamous cell carcinoma.
8047 Background: While neoadjuvant immunotherapy (nIO) is the standard of care for resectable NSCLC, its efficacy in "pote...
Determinants of metastatic phenotypes at diagnosis in prostate cancer: A population-based analysis of organotropism, disparities, and clinical implications.
e17113 Background: Metastatic prostate cancer is biologically heterogeneous, yet metastatic sites are often grouped togeth...
Financial toxicity and health-related social needs in adolescent and young adult cancer patients and their caregivers: Insights from an LMIC population.
e23180 Background: Adolescents and young adults with cancer experience substantial financial toxicity (FT) and health-rela...
PKCI–YAP1–CCL7 axis and tumor-associated macrophage–mediated anti–PD-1 resistance in lung adenocarcinoma.
e20619 Background: Immune checkpoint blockade targeting PD-1 has improved outcomes in non-small cell lung cancer (NSCLC),...
Using the NCCN distress thermometer to evaluate clinically elevated levels of distress among caregivers of HSCT patients.
12093 Background: Caregivers of patients receiving an allogeneic hematopoietic stem cell transplant (HSCT) play a vital ro...
Proof of concept for machine learning–based models to predict response to anticancer treatments.
e13002 Background: Selecting the most effective anticancer drugs remains challenging. Comprehensive molecular profiling id...
Androgen receptor (AR) gene dynamics in ctDNA post-abiraterone/enzalutamide: Longitudinal study in mCRPC with germline results.
5076 Background: Approximately 10–15% of men with metastatic prostate cancer harbor germline mutations. Circulating tumor...
Severe cognitive effects of avapritinib: Towards a mechanistic understanding.
e24164 Background: Approximately 5-10% of Gastrointestinal Stromal Tumors (GIST) harbor a PDGFRα D842V mutation. For patie...
A phase 1b/2 study of QLS1304, a novel, highly potent, and selective dual inhibitor of KAT6A/6B, plus endocrine therapy (ET) in patients (pts) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC).
TPS1144 Background: QLS1304 is a novel, highly-potent, and selective dual inhibitor of KAT6A/6B. KAT6A acetylates histone...
Circulating tumor DNA clearance of adjuvant chemotherapy in localized colorectal cancer using an ultrasensitive structural variant–based assay.
3625 Background: High-risk localized colorectal cancer (CRC) remains prognostically unfavorable. Adjuvant chemotherapy (AC...